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Aims Sudden cardiac death (SCD) is the most common mode of death in childhood hypertrophic cardiomyopathy
(HCM). The newly developed HCM Risk-Kids model provides clinicians with individualized estimates





A retrospective, longitudinal cohort of 421 patients diagnosed with HCM aged 1–16 years independent of the
HCM Risk-Kids development and internal validation cohort was studied. Data on HCM Risk-Kids predictor varia-
bles (unexplained syncope, non-sustained ventricular tachycardia, maximal left ventricular wall thickness, left
atrial diameter, and left ventricular outflow tract gradient) were collected from the time of baseline clinical
evaluation. The performance of the HCM Risk-Kids model in predicting risk at 5 years was assessed. Twenty-
three patients (5.4%) met the SCD end-point within 5 years, with an overall incidence rate of 2.03 per 100
patient-years [95% confidence interval (CI) 1.48–2.78]. Model validation showed a Harrell’s C-index of 0.745
(95% CI 0.52–0.97) and Uno’s C-index 0.714 (95% 0.58–0.85) with a calibration slope of 1.15 (95% 0.51–1.80). A
5-year predicted risk threshold of >_6% identified 17 (73.9%) SCD events with a corresponding C-statistic of
0.702 (95% CI 0.60–0.81).
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Conclusions This study reports the first external validation of the HCM Risk-Kids model in a large and geographically diverse
patient population. A 5-year predicted risk of >_6% identified over 70% of events, confirming that HCM Risk-Kids
provides a method for individualized risk predictions and shared decision-making in children with HCM.
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Introduction
Sudden cardiac death (SCD) is the most common mode of death in
childhood hypertrophic cardiomyopathy (HCM) outside of infancy
and occurs more frequently than in adult patients.1–3 Despite this,
identification of patients who might benefit from primary prevention
implantable defibrillator (ICD) implantation remains challenging, as
current risk tools have been shown to have a limited ability to dis-
criminate between those at high and low risk.4 In 2019, we developed
a risk prediction model for SCD in childhood HCM (HCM Risk-Kids),
using data from 1024 patients.5 This model, which uses readily avail-
able non-invasive clinical variables, had superior discriminatory ability
on internal validation analysis than the currently recommended
approaches to risk stratification6,7 but has not yet been externally
validated in an independent population. The aim of this study was to




The study cohort comprised consecutively evaluated patients aged 1–
16 years meeting diagnostic criteria for HCM from nine participating
centres in the International Paediatric Hypertrophic Cardiomyopathy
Consortium and the Sarcomeric Human Cardiomyopathy Registry
(SHaRe) (Supplementary material online, Table S1). SHaRe centres that
had contributed data to the HCM Risk-Kids development cohort were
excluded. Included patients were evaluated between 1995 and 2019.
Hypertrophic cardiomyopathy was defined as a maximal left ventricular
wall thickness (MLVWT) of more than two standard deviations (SDs)
above the body surface area (BSA)-corrected mean in the absence of ab-
normal loading conditions that could account for the abnormality.6
Patients were excluded if they had a prior history of ventricular fibrillation
or sustained ventricular tachycardia (VT), known inborn errors of metab-
olism or syndromic disease (e.g. Friedreich’s ataxia, RASopathy syndrome),
<1-month follow-up, or missing data for more than 50% of HCM Risk-
Kids model predictor variables (Supplementary material online, Figure S1).
Patient assessment and data collection
Anonymized clinical data from baseline evaluation were collected retro-
spectively, including demographics, heart failure symptoms [New York
Heart Association (NYHA) or Ross functional classification], pedigree
analysis, resting and ambulatory 12-lead electrocardiogram (ECG), and
two-dimensional (2D) Doppler and colour transthoracic echocardio-
gram. Hypertrophic cardiomyopathy Risk-Kids5 predictor variables were
recorded at the time of, or prior to baseline evaluation: specifically, unex-
plained syncope (defined as a transient loss of consciousness with no
identifiable cause), non-sustained ventricular tachycardia (NSVT) (defined
as >_3 consecutive ventricular beats at a rate of >_120 beats per minute
lasting <_30 s on ambulatory ECG monitoring), MLVWT Z score,8 left
atrial (LA) diameter Z score (defined as the number of SDs away from
population mean the 2D measurement of LA diameter),9 and maximal
left ventricular outflow tract (LVOT) gradient (defined as the maximal
LVOT gradient at rest or with Valsalva provocation using continuous
wave Doppler from apical three- or five-chamber views). Family history
of SCD was defined as the sudden death of one or more first-degree rela-
tives <40 years, or sudden death in a first-degree relative with a diagnosis
of HCM at any age.6 Data were collected independently at participating
centres and data integrity is guaranteed by each participating author.
Clinical outcomes
The primary study end-point was SCD or an equivalent event (aborted
cardiac arrest, appropriate ICD therapy for a ventricular tachyarrhythmia,
or sustained VT associated with haemodynamic compromise5) SCD was
defined as a witnessed sudden death with or without documented cardiac
failure, death within 1 h of new symptoms, or nocturnal deaths with no
history of worsening symptoms.6 Outcomes were determined by the
treating cardiologist at each centre without knowledge of the HCM Risk-
Kids estimates.
Statistical methods
Statistical analysis was performed using Stata statistical software (Version
14) and R studio (Version 1.7). Variables are described as mean ± SD, me-
dian [interquartile range (IQR)], and counts or percentages as appropri-
ate. Group comparisons were performed using the Student’s t-test,
Mann–Whitney, or v2 test as appropriate. Follow-up time was calculated
from the time of baseline evaluation to the date of reaching the study
end-point, death from another cause, or date of most recent evaluation.
The Kaplan–Meier method was used to estimate the incidence of reach-
ing the study end-point. Univariable Cox regression models were used to
investigate the association of clinical variables with the study end-point.
What’s new?
• In a large and geographically diverse patient population, a 5-year hypertrophic cardiomyopathy (HCM) Risk-Kids predicted sudden cardiac
death risk of >_6% identified over 70% of events.
• This study confirmed that HCM Risk-Kids provides a validated individualized tool for shared decision-making to guide implantable
defibrillator implantation in children with HCM.







































































































Patients with more than three HCM Risk-Kids predictor variables missing
were excluded from the validation cohort. Data were assumed to be
missing at random and missing predictors were imputed using multiple
imputations techniques based on chained equations.10 The imputation
model included potential predictors of missingness, the outcome, HCM
Risk-Kids predictor variables, and the estimate of the Nelson Aalen cu-
mulative hazard function. A total of 75 imputed datasets were created.
Estimates from imputed datasets were combined using Rubin’s rule.11
Hypertrophic cardiomyopathy Risk-Kids model validation
Follow-up was censored at 5 years and the estimated 5-year risk of SCD
was calculated for each individual patient using the HCM Risk-Kids
model:5
PðSCD at 5-yearsÞ ¼ 1-0:949437808expðprognostic indexÞ;
where prognostic index = 0.2171364 (MWT z score 11.09)
 0.0047562 (MWT z score2–174.12) þ 0.130365 (LA diameter z
score 1.92) þ 0.429624 unexplained syncope þ 0.1861694
NSVT 0.0065555 (maximal LVOT gradient 21.8).
The C-index (Uno and Harrell’s) was used to measure how well the
model discriminated between high- and low-risk patients (a value of 1
indicates perfect discrimination, while a value of 0.5 indicates no discrim-
ination).12–14 Bootstrapping was used to calculate the confidence inter-
vals (CIs) for Uno’s C-index. Harrell’s C-index is subject to bias if the
amount of censoring is high13 but is presented to enable comparison with
alternative paediatric risk models. The calibration slope was used to as-
sess the degree of agreement between the observed and predicted risk
of SCD (a value close to 1 suggests good overall agreement).15 Model
calibration was described graphically by stratifying patients into three risk
groups based on tertiles of model predicted 5-year risk of SCD event
from one imputed dataset.
The positive predictive value (PPV) of using different thresholds of
HCM Risk-Kids estimated risk at 5 years in one imputed dataset was cal-
culated by dividing (sensitivity prevalence) by [(sensitivity preva-
lence) þ (1 specificity) (1 prevalence)] and expressed as a
percentage. The negative predictive value (NPV) was calculated by divid-
ing [specificity (1 prevalence)] by [(1 sensitivity prevalence) þ
(specificity) (1 prevalence)] and expressed as a percentage.
Validation of hypertrophic cardiomyopathy Risk-Kids
threshold (6%)
Current European Society of Cardiology (ESC) guidelines in adult
patients recommend ICD implantation in the presence of an estimated
5-year risk of SCD >_6%.6 The discriminatory ability of using an estimated
5-year HCM Risk-Kids SCD risk threshold of >_6% was assessed and the
C-statistic was calculated.
Ethics
This study complies with the Declaration of Helsinki. Local ethical ap-
proval was given for each collaborating centre with waiver of informed
consent for retrospective, anonymized data.
Results
Baseline clinical characteristics
The study cohort consisted of 421 patients (males n = 258, 64%) eval-
uated over a 30-year period [1990–1999 n = 11 (2.6%); 2000–2009
n = 89 (21.1%); 2010–2020 n = 321 (76.3%)] with a median age at
baseline evaluation of 12.3 years (7.3, 14.4) (Figure 1A). Two hundred
and fifty (59.4%) of these were recruited from the SHaRe registry
(Supplementary material online, Table S1). Baseline clinical character-
istics are summarized in Table 1. Compared to the HCM Risk-Kids
development and internal validation population, this cohort of
patients was slightly older at baseline evaluation [median age 12.3
(7.3–14.4) vs. 11 (7–14) years, P = 0.0001] and had a shorter follow-
up time [median follow-up 3.5 (1.8–6.6) vs. 5.3 (2.6–8.3) years,
P = 0.0001]. Differences in baseline clinical characteristics are sum-
marized in Table 1.
Clinical outcomes and sudden cardiac
death end-points
The validation study cohort had a median total follow-up of
3.48 years (IQR 1.83–6.62; range 1 month–20.7 years). Fourteen
patients (3.3%) died and 10 (2.4%) underwent cardiac transplant-
ation. Cause of death was SCD (n = 10), heart failure related (n = 1),
other cardiovascular (CV) (n = 1), non-CV (n = 1), and unknown
(n = 1). Annual and 5-year cumulative mortality or transplant inci-
dence rates were 1.24% (95% CI 0.52–2.96) and 5.21% (95% CI
0.31–8.70), respectively. Four patients (1.0%) were lost to follow-up.
Thirty-nine patients (9.3%) experienced an SCD or equivalent event
(SCD n = 10; resuscitated cardiac arrest n = 11; appropriate ICD
therapy for ventricular tachyarrhythmia n = 16; sustained VT with
haemodynamic compromise n = 2), with an overall incidence of 2.03
per 100 patient-years (95% CI 1.48–2.78) (Figure 2A). Annual and
5-year cumulative incidence of an SCD or equivalent event was
1.49% (95% 0.67–3.29) and 8.6% (95% CI 6.67–13.0), respectively.
Analyses were focused on the 23 patients who had SCD or equiva-
lent events within 5 years of follow-up (Figure 1B). Baseline charac-
teristics in those with and without an SCD or equivalent event at
5 years are shown in Table 2.
Missing data
Missing data were seen in 1, 2, or 3 predictor variables in 122
(29.0%), 89 (21.1%), and 87 (20.7%) patients, respectively. There
were missing data for four of five HCM Risk-Kids predictor variables
(Table 1). A comparison of the distribution of predictors before and
after imputation is shown in Supplementary material online, Table S2.
The proportion of missing data for HCM Risk-Kids predictor varia-




The performance of the HCM Risk-Kids model in predicting risk at
5 years was assessed in 421 patients with 23 events. Harrell’s C-index
was 0.745 (95% CI 0.52–0.97) and Uno’s C-index 0.714 (95%
CI 0.58–0.85). The calibration slope was 1.15 (95% CI 0.51–1.80).
Table 3 and Figure 3A describe the agreement between predicted and
observed 5-year cumulative proportion of SCD or equivalent events
for each tertile of predicted risk in one imputed dataset.
Validation of using a predicted risk of 6%
In a single imputed dataset, 125 (29.7%) patients had a predicted
5-year risk of >_6%. Sudden cardiac death events occurred in


























6 patients (2.0%) with a predicted risk <6% and 17 (13.6%) with a
predicted risk >_6. The clinical characteristics of those patients experi-
encing an SCD event with a predicted risk <6% is described in
Supplementary material online, Table 4. Five-year survival free from
SCD or an equivalent event was 96.5% (95% CI 92.2–98.5) and
81.3% (95% CI 71.1–88.2), respectively, with a corresponding hazard
ratio of 6.16 (95% CI 2.43–15.65, P < 0.001) (Figure 2B). The
combined C-statistic for all imputed datasets for using a 5-year pre-
dicted risk threshold of >_6% was 0.702 (95% CI 0.60–0.81). Figure 3B
describes the agreement between predicted and observed 5-year
cumulative proportion of SCD events using a threshold of >_6%. The
positive and negative predictive value of using different thresholds of
HCM Risk-Kids estimated risk (>_5, >_6, >_7, >_8) to guide ICD implant-
ation decisions are shown in Supplementary material online, Table S5.
Figure 1 Bar chart showing (A) age at presentation and (B) age at sudden cardiac death event by timing after baseline clinical follow-up.
....................................................................................................................................................................................................................
Table 1 Baseline clinical characteristics
Clinical characteristic Validation cohort
(n 5 421)
HCM Risk-Kids development
cohort (n 5 1024)
P-value
Male gender (n = 403) 258 (64.0%) 699 (68.3%) 0.125
Age, median (Q1–Q3) 12.3 (7.3–14.4) 11 (7–14) 0.0001
NYHA/Ross (n = 154)
1 110 (71.4%) 783 (77.8%) 0.079
>_2 44 (28.6%) 223 (22.2%)
Family history HCM 198 (47.0%) 534 (53.1%) 0.037
Family history SCD 47 (11.2%) 130 (12.8%) 0.406
Unexplained syncope 15 (3.6%) 102 (9.9%) <0.0001
NSVT (n = 246) 8 (3.3%) 55 (6.4%) 0.059
MWT (mm) (n = 408), mean ± SD 16.5 ± 7.8 17.1 ± 7.4 0.1207
MWT z score (n = 354)
Median (Q1–Q3) 7.6 (4.7–13.6) 8.9 (5.8–14.9) <0.0001
Mean ± SD 9.8 ± 7.3 11.1 ± 7.1 0.0025
LA diameter (mm) (n = 292), mean ± SD 30.8 ± 9.0 33.4 ± 8.5 <0.0001
LA diameter z score (n = 264), mean ± SD 1.3 ± 2.4 1.9 ± 2.3 0.0003
LVOT gradient (n = 205), median (Q1–Q3) 9 (5–24) 9 (6–22) 0.0469
LVOT obstruction (>_30 mmHg) (n = 234) 45 (22.0%) 189 (18.4%) 0.2448
Comparisons are made using v2 test for categorical variables and unpaired t-test or Mann–Whitney for continuous variables. For clinical characteristics N = 421 unless otherwise
indicated.
HCM, hypertrophic cardiomyopathy; LA, left atrium; LVOT, left ventricular outflow tract obstruction; MWT, maximal wall thickness; NSVT, non-sustained ventricular
tachycardia; NYHA, New York Heart Association; SCD, sudden cardiac death; SD, standard deviation.





































This study reports the first external validation of the HCM Risk-Kids
model in a large, independent, and geographically diverse patient
population. A 5-year predicted risk of >_6% identified over 70% of
events, confirming that HCM Risk-Kids provides a validated individu-
alized tool for shared decision-making to guide ICD implantation in
children with HCM.
External validation of the hypertrophic
cardiomyopathy Risk-Kids model
In 2019, the first validated risk prediction model for SCD in childhood
HCM (HCM Risk-Kids5) which uses readily available non-invasive
Figure 2 Kaplan–Meier curves showing event-free survival (A) for whole cohort (B) by risk category ‘high risk’ (hypertrophic cardiomyopathy
Risk-Kids estimated 5-year risk >_6%) and ‘low risk’ (hypertrophic cardiomyopathy Risk-Kids estimated 5-year risk <6%) [hazard ratio of 6.16
(95% confidence interval 2.43–15.65), P < 0.001]. CI, confidence interval.
....................................................................................................................................................................................................................
Table 2 Baseline clinical characteristics of patients with and without sudden cardiac death end-points at 5 years







Male gender (n = 403) 15 (65.2%) 243 (64.0%) 1.00 (0.43–2.37) 0.993
Age (years), median (Q1–Q3) 12.6 (10.6–14.8) 12.2 (7.1–14.4) 1.06 (0.96–1.18) 0.242
NYHA/Ross 2þ 5 (26.3%) 39 (28.9%) 0.94 (0.34–2.26) 0.911
Family history HCM 15 (62.2%) 183 (46.0%) 1.84 (0.78–4.33) 0.166
Family history SCD 4 (17.4%) 43 (10.8%) 1.38 (0.47–4.06) 0.562
Unexplained syncope 4 (17.4%) 11 (2.8%) 6.76 (2.29–19.94) 0.001
NSVT (n = 246) 1 (5.6%) 7 (3.1%) 1.19 (0.16–9.00) 0.868
MWT z score (n = 354), median (Q1–Q3) 14.7 (9.0–18.3) 7.4 (4.6–13.1) 1.06 (1.01–1.11) 0.013
LA diameter z score (n = 264), mean ± SD 1.2 ± 2.4 2.0 ± 2.5 1.14 (0.97–1.35) 0.121
LVOT gradient (n = 205). median (Q1–Q3) 5.8 (5–9) 9 (4.8–25) 0.99 (0.97–1.01) 0.406
LVOT obstruction (>_30 mmHg) (n = 234) 41 (22.3%) 41 (19.1%) 0.95 (0.32–2.83) 0.928
CI, confidence interval; HCM, hypertrophic cardiomyopathy, LA, left atrial, LVOT, left ventricular outflow tract, MWT, maximal wall thickness, NYHA, New York Heart
Association, NSVT, non-sustained ventricular tachycardia, SCD, sudden cardiac death; SD, standard deviation.
.................................................................................................
Table 3 Observed vs. hypertrophic cardiomyopathy












Low risk <2.60 1.66 2.49% (0.59–10.21)
Medium risk 2.61–5.50 3.78 3.95% (1.23–12.28)
High risk >5.50 9.58 17.42% (11.14–26.67)
CI, confidence interval,
Calculated from one imputed dataset.



































































..clinical variables to estimate the risk of an SCD event occurring with-
in 5 years was published. Internal validation of this model in the devel-
opment cohort showed it to have superior performance for
predicting SCD risk in children with HCM compared to a previously
published external validation of current paediatric European6 and
North American guidelines7 (C-index 0.69 vs. C-statistic 0.624). This
finding has been corroborated in the only small external validation
study of the HCM Risk-Kids model to date, which reported a C-statis-
tic of 0.771 and 0.677 for a HCM Risk-Kids 5-year estimated risk
threshold of >_4% and >_6%, respectively.16 In the present study, we
provide the first large-scale external validation of this model, confirm-
ing its superior ability to identify patients at high risk of SCD events
(Harrell’s C-index 0.75 and Uno’s C-index 0.71). Compared to the
development cohort, the external validation cohort was older at
baseline and had a lower prevalence of traditional clinical risk factors
for SCD, which could suggest that they had phenotypically milder dis-
ease. The proportion of patients with unexplained syncope, for ex-
ample, was lower than in the development cohort (3.6% vs. 9.9%),
but comparable to estimates from previously published population
studies (3–18%).2,3,17 This likely represents variability in the pheno-
type of childhood HCM but could also be explained by under-
reporting of symptoms in retrospective population studies. Although
the validation cohort had markers of phenotypically milder disease,
the incidence of SCD event rates was not different between the two
populations. The finding that the HCM Risk-Kids model has good dis-
criminatory ability despite the differences in baseline clinical pheno-
type could strengthen its clinical utility. However, it is possible that
the demographics and phenotype of the cohort could have resulted
in higher estimates of performance than would be seen in real-world
practice. The accuracy of risk estimates was better for those at lower
risk of events and, in common with adult risk stratification models,
appeared to be under-estimated for those at highest risk. Although
this is unlikely to affect a clinicians’ decision to implant an ICD in an in-
dividual patient, prospective studies are required to investigate how
the risk model performs in clinical practice.
Clinical application of the hypertrophic
cardiomyopathy Risk-Kids model
There is currently no consensus on the absolute SCD risk that justi-
fies ICD implantation during childhood and potential benefits must
be balanced with the increased risk of device-related complications
seen in young patients.18 The 2014 adult ESC guidelines recommend
using a 5-year estimated risk threshold of >_6%, calculated using the
HCM Risk-SCD model,19 to guide ICD implantation but recognize
that an ICD may also be appropriate in intermediate risk patients (4–
6% risk at 5 years).6 By way of comparison, we explored the clinical
impact of using a threshold of >_6% in childhood HCM. One-third of
patients had a 5-year HCM Risk-Kids estimated SCD risk of >_6% and
using this threshold to guide ICD implantation identified 74% (17/23)
of SCD events. A previous validation study of the current paediatric
guidelines reported that 3% (14/411) and 31% (127/411) met ICD
recommendation thresholds identifying 7% (23/43) and 51% (22/43)
SCD events for the European and North American guidelines, re-
spectively. The discriminatory ability of a HCM Risk-Kids estimated
SCD risk of >_6% for identifying those at risk of SCD events is there-
fore substantially higher than current European and North American
guidelines (C-statistic 0.70 vs. 0.62)4, and comparable to the perform-
ance of the adult HCM Risk-SCD model.19,20 Of those patients expe-
riencing an SCD event with a low HCM Risk-Kids predicted risk of
SCD, all but one had clinical features of mild disease and would also
not have been recommended for ICD implantation using the current
European or North American guidelines. This demonstrates a prob-
lem common to all risk models and reinforces the central role that
clinical decision-making should play in risk stratification decisions.
Seven in eight patients who had an ICD implanted for a risk of >_6%
did not experience an appropriate ICD therapy within 5 years, with
the accompanying burden of ICD-related complications, which are
recognized to be higher in a paediatric population. However, as the
risk of an arrhythmic event persists throughout childhood into ado-
lescence and adulthood,21 a subset of these patients may yet benefit
Figure 3 Comparison of observed and predicted risk in one imputed dataset by (A) predicted risk tertile (B) risk category ‘high risk’ (hypertrophic
cardiomyopathy Risk-Kids estimated 5-year risk >_6%) and ‘low risk’ (hypertrophic cardiomyopathy Risk-Kids estimated 5-year risk <6%). Vertical
bars represent observed (dark blue) and hypertrophic cardiomyopathy Risk-Kids model predicted (red) probability of sudden cardiac death event by
5 years follow-up. SCD, sudden cardiac death.






































































































from ICD implantation. Additionally, subcutaneous ICD devices offer
the hope that the future burden of ICD-related complications will be
lower for younger patients receiving primary prevention devices.
Adopting a threshold for HCM Risk-Kids estimated risk could be a
useful adjunct to facilitate shared decision-making between patients,
families, and clinicians around ICD implantation in childhood HCM.
Yet, given the low incidence of mortality secondary to competing
causes, a threshold of 6% may be inappropriate for childhood disease
and expert consensus opinion would be required to determine an
appropriate risk threshold. The HCM Risk-Kids model was devel-
oped to predict 5-year SCD risk at first evaluation and validated in
patients up to the age of, and including, 16 years of age. The ESC
guideline-adopted validated adult HCM Risk-SCD model should be
used for patients beyond that age.6,19 Importantly, although HCM
Risk-Kids has superior discriminatory ability compared to current
guidelines, in real work clinical practice it remains imperfect with
patients at risk of events unprotected and a high number of patients
without an event exposed to the risk of device-related complications.
Future iterations of HCM Risk-Kids using serial clinical data to enable
reassessment of risk during follow-up and identification of other
novel risk factors are needed to improve outcomes.
Comparison with other paediatric risk
models
Since the publication of HCM Risk-Kids, a separate paediatric-specific
model was developed in a North American multi-centre retrospect-
ive cohort (PRIMaCY) of 572 patients up to 18 years of age.3 Both
models use readily available clinical predictors, chosen based on ei-
ther three decades of published literature (HCM Risk-Kids)5 or an as-
sociation with the end-point of an arrhythmic event in a development
cohort (PRIMaCY).3 Despite the different approaches to predictor
selection, the variables included in the two models are almost identi-
cal, reflecting clinical markers of disease severity. Important differen-
ces include the measure of left ventricular hypertrophy (MLVWT vs.
interventricular septal and posterior wall thickness) and use of age at
diagnosis as a predictor variable in the PRIMaCY model. Age is not
included in HCM Risk-Kids as, with the exception of infant-onset dis-
ease, there is limited evidence that it is important for risk stratifica-
tion1,22–24 and including it as a predictor during model development
did not improve model performance.5 However, the effect of age is
likely to have been partially accounted for by the use of BSA-
corrected echocardiographic measurements. A subset of the SHaRe
cohort also served as the validation cohort for the PRIMaCY model
and model performance and discriminatory ability was higher for
HCM Risk-Kids (Harrell’s C-index 0.75 vs. 0.71). Although CIs for the
performance estimates were not reported for the PRIMaCY model,
given that both the development and internal validation and the ex-
ternal validation cohorts for the HCM Risk-Kids model are nearly
twice as large as PRIMaCY, they would be expected to be at least as
wide as in our own external validation cohort, reflecting uncertainty
in the estimates due to small patient numbers and missing data. The
estimate of Harrell’s C-index may be subject to bias in the presence
of moderate to high levels of censoring and Uno’s C-index has been
recommended for use in these situations.13 Further independent
prospective external validation studies of these two models are
needed to compare performance in clinical practice, but the results
of this study suggest that HCM Risk-Kids outperforms current
European and North American guidelines and has a similar discrimin-
atory performance to the adult HCM Risk-SCD model.6,7,20
Future directions
In order to facilitate ongoing reassessment of HCM Risk-Kids in tem-
porally and geographically diverse populations, we have made the
model widely available (www.hcmriskkids.org) to improve accessibil-
ity for clinicians. Incorporation of the model into clinical practice will
provide contemporary data for prospective validation studies.
Childhood HCM is characterized by significant heterogeneity and
phenotype, and therefore risk profile may change before transition to
adult care, representing a challenge for risk prediction strategies.2
Hypertrophic cardiomyopathy Risk-Kids was designed to be used at
baseline clinical assessment, regardless of proband status, to predict
the risk of an SCD event occurring within 5 years of follow-up.
However, in clinical practice, reassessment of a patient’s risk during
follow-up taking into account the changing cardiac phenotype would
be of clinical benefit. Future studies exploring the changing role of in-
dividual clinical risk factors during childhood and the use of serial clin-
ical data to predict time-dependent risk are required. This could be
particularly important for patients presenting through family screen-
ing, who may have milder disease at baseline compared to childhood
family probands. The role of genotype in risk prediction for children
and adults with HCM remains unclear.21,25 Although a disease-
causing sarcomeric variant was associated with an SCD event in the
PRIMaCY cohort, including it in the risk prediction model did not sig-
nificantly improve model accuracy.3 Previous studies have been lim-
ited by their retrospective, longitudinal design meaning genetic
testing was not systematically performed in all patients. Data on gen-
etic testing were not systematically collected in this cohort but future
large-scale prospective multi-centre registries are needed to explore
the genotype–phenotype correlations in childhood HCM. Late gado-
linium enhancement (LGE) on cardiac magnetic resonance imaging
has been shown to be an independent risk factor for SCD or equiva-
lent events in adult HCM populations26 and recent studies have
shown that the presence of LGE could improve risk stratification,
particularly for patients with an intermediary 5-year ESC SCD risk
score.27,28 Paediatric studies to date have been underpowered to de-
tect a difference in SCD risk29 but, the presence of, or degree of LGE
has been reported to improve the discriminatory ability of HCM
Risk-Kids model in a small single-centre study.17 Future studies to
confirm the role of LGE in risk stratification for childhood HCM and
its inclusion in future iterations of HCM Risk-Kids model should be
explored. This study did not aim to validate the use of HCM Risk-
Kids in patients with infant-onset or syndromic causes of left ventricu-
lar hypertrophy (LVH) (e.g. inborn errors of metabolism, RASopathy
syndrome, or neuromuscular disorders) and indeed the model is not
currently validated for use in these patient groups, as they were
excluded from the model development cohort. These groups of
patients are recognized to have a worse overall prognosis, with death
most commonly attributed to heart failure or non-cardiac causes.
Future studies to explore the risk of SCD and impact that competing
causes of mortality have on risk stratification for these patient groups
are needed.







































































































This study is limited by its retrospective longitudinal design, as necessi-
tated for a rare condition with low event rates. The most significant
limitations, in common with other paediatric and adult HCM cohort
studies, are missing data and the relatively low number of events. The
proportion of missing data was higher than in the HCM Risk-Kids de-
velopment cohort but similar to the PRIMaCY validation cohort. This
may partly be explained by the use of contemporaneously written
echocardiographic reports, different local echocardiographic scanning
protocols, and difficulty in obtaining some investigations in younger
patients (e.g. ambulatory ECGs). To ensure our imputation of missing
data was robust, we incorporated all predictors in the imputation
model that we considered to be important to explain missingness. A
comparison of the distribution of predictors before and after imput-
ation confirmed that the distributions were similar and had not been
distorted. As the external validation cohort was smaller, despite having
a similar overall annual SCD event rate, there was a low number of
events (n = 23) within 5 years, resulting in wide CIs for the estimated
annual incidence rate. The true incidence of SCD events occurring in
childhood HCM is unknown, but large population studies have
reported an annual incidence rate of 1–2%1–3 suggesting that the out-
comes of this study population are representative of the wider child-
hood HCM. The small population sample and low event rate resulted
in wide CIs for the C-index and the calibration slope values, which rep-
resents uncertainty in the estimates. The median length of follow-up
for the validation cohort was shorter than the development cohort
and only two-fifths of patients had a follow-up of 5 years or longer. The
HCM Risk-Kids model predicts the risk of an SCD event occurring
within 5 years of follow-up meaning that patients with shorter follow-
up times could still reach the SCD end-point within 5 years. This could
affect the estimates of predictive accuracy (negative and positive pre-
dictive value) for the model. The limitations of the study design could
be addressed with future prospective, large multi-centre studies assess-
ing the performance of risk prediction models in childhood HCM.
Finally, the number of patients who underwent surgical gradient
reduction (myectomy) was small; our current understanding of the
impact surgical gradient reduction has on risk is limited and the model
should therefore be used cautiously in this patient group.
Conclusions
This study shows that the HCM Risk-Kids model has superior ability
to identify childhood patients at high risk for SCD over 5 years com-
pared to current risk stratification guidelines and alternative paediat-
ric risk models with over 70% of events predicted by an estimated
risk of >_6%. The model provides a validated individualized tool for
shared decision-making to improve risk stratification and guide ICD
implantation in children with HCM. Incorporation of the model into
routine clinical care will enable independent prospective model valid-
ation and assessment of the effect of its use in clinical practice.
Supplementary material
Supplementary material is available at European Journal of Preventive
Cardiology.
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